Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORYN 1062
- Development stage
- Preclinical
- Lead developer
- Oryn Therapeutics
- Modality
- Peptides
01
Overview
ORYN 1062 is a synthetic peptide drug candidate developed by Oryn Therapeutics. It is being investigated for the treatment of infectious diseases, specifically mycoses (fungal infections). The drug is currently in preclinical development and has not yet entered clinical trials. Detailed information about its mechanism of action or specific molecular targets has not been disclosed publicly[1][4].
Beyond the preview
Go deeper on ORYN 1062.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORYN 1062.